"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 11 | 11 |
| 2004 | 0 | 8 | 8 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 5 | 6 |
| 2008 | 1 | 7 | 8 |
| 2009 | 1 | 9 | 10 |
| 2010 | 0 | 9 | 9 |
| 2011 | 3 | 8 | 11 |
| 2012 | 4 | 9 | 13 |
| 2013 | 4 | 6 | 10 |
| 2014 | 6 | 4 | 10 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 3 | 7 | 10 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 6 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 2 | 10 | 12 |
| 2024 | 4 | 3 | 7 |
| 2025 | 2 | 4 | 6 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. Clin Cancer Res. 2026 May 15; 32(10):1973-1982.
-
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
-
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol. 2026 May; 89(5):396-403.
-
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. Clin Transl Sci. 2025 12; 18(12):e70425.
-
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28; 146(9):1065-1077.
-
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025 Jul 14; 16(1):522.
-
Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients. Leukemia. 2025 08; 39(8):1915-1927.
-
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025 08 10; 43(23):2606-2615.
-
Dual Targeting EZH2 and Histone Deacetylases in Human Uterine Sarcoma Cells Under Both 2D and 3D Culture Conditions. J Cell Mol Med. 2025 06; 29(11):e70626.
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e258751.